The prevalence of insulin monotherapy in T2DM in Europe is unknown, but a study from 2018 estimated that the T2DM insulin users’ values in the United Kingdom, Sweden, and Denmark were 12.5%, 11.7%, and 15.8%, respectively. This evidence concerns the gene INS and type 2 diabetes mellitus.